Opinion of the Transparency Council – cyclophosphamidum

At its meeting on 16 August 2022 the Transparency Council adopted Opinion No. 129/20022 on the active substance cyclophosphamidum for the indications: sarcoidosis; interstitial pneumonia – in cases other than those specified in the SmPC – with the exception of idiopathic pulmonary fibrosis.

Publication with the minutes of the Transparency Council meeting